The HALT polycystic kidney disease trials: design and implementation. - Wikidata - wikimedia - TriplyDB

The HALT polycystic kidney disease trials: design and implementation.

The HALT polycystic kidney disease trials: design and implementation.

http://www.wikidata.org/entity/Q33571347

about

Interventions for preventing the progression of autosomal dominant polycystic kidney disease Current management of autosomal dominant polycystic kidney disease Spanish guidelines for the management of autosomal dominant polycystic kidney disease Decreased Polycystin 2 Levels Result in Non-Renal Cardiac Dysfunction with Aging Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease Evaluation and management of pain in autosomal dominant polycystic kidney disease.Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.Bioactive lipid mediators in polycystic kidney disease Hypertension in autosomal dominant polycystic kidney disease.Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.Treatment strategies and clinical trial design in ADPKD Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4α as a disease modifier.Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways.Endothelial dysfunction and oxidative stress in polycystic kidney disease.Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.Liver involvement in early autosomal-dominant polycystic kidney disease Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants Angiotensin blockade in late autosomal dominant polycystic kidney disease.Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2 Blood pressure in early autosomal dominant polycystic kidney disease.Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease Closeout of the HALT-PKD trials Analysis of baseline parameters in the HALT polycystic kidney disease trials.Novel drugs and intervention strategies for the treatment of chronic kidney disease.Which antihypertensive drugs are the most nephroprotective and why?Drug discovery for polycystic kidney disease Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies.Improving the efficacy of RAAS blockade in patients with chronic kidney disease.New treatments for autosomal dominant polycystic kidney disease Evidence for a role of proteins, lipids, and phytochemicals in the prevention of polycystic kidney disease progression and severity.Pharmacological management of polycystic kidney disease.Rationale for early treatment of polycystic kidney disease.Novel therapeutic approaches to autosomal dominant polycystic kidney disease.Clinical Trials and a View Toward the Future of ADPKD.

P2860

Q24186484-C3648709-CF00-4682-B740-600615960CE5 Q26784073-7611DA15-24D4-4336-81D3-9F55B580BC45 Q26863397-6095405F-FCEF-4C93-AE3A-2A594B267512 Q27313611-702EB264-670B-46FB-843D-E4DA95273AB7 Q27320627-55CE1B18-B3C7-4620-AEDB-0F8C8B42657E Q30432353-0400255C-AA45-45D5-A07F-DB751DE8E472 Q30870783-0773A3D2-D0A9-4180-9B1F-C69E3381B206 Q33571758-A5A4B2E3-DC52-41A7-BAD4-4A4AA9A8E591 Q33653643-B739E1CA-01C7-4165-B1C6-65D865DDB533 Q33754691-EA6D7A05-E921-44DA-9407-732FB835FC38 Q33820977-51C54B53-053E-4554-98A5-BA2003790354 Q34024396-99A45046-3741-4839-8175-270FE9C5A82B Q34423262-242AA117-B904-40D0-995A-7DF47C032013 Q34497281-47333492-30B7-49AC-9FAE-7EFE611B5261 Q34499444-86C754B6-3286-4388-9D3F-CFFFF3A428E6 Q34581173-4A0D290D-F36C-4183-8B15-2DCBCFCBC62F Q34627589-9DE9032C-E3F8-493B-9A58-D66E6332F06F Q34699683-21A9E409-EEB2-48AD-B4EF-9F2FD8862821 Q34713846-1F531CBB-9469-4A67-9E43-C44866A93C13 Q34796003-CF63E627-9152-40BE-AE4F-B4A3DEFD759F Q34836649-D71CC72D-9C64-4901-8752-5108C3309571 Q35086449-C5ADB33E-3CA3-4460-ADFB-2BBA6EFAD064 Q35129320-CFC3D116-AD15-45F5-8A9B-EC447806F3F8 Q35267218-2D3F5B3E-C673-4496-8C44-BFF16B868B1F Q35466141-E18F8D47-F0E3-4776-ACF1-88A4359A8675 Q35827271-4DD95A41-592C-41AE-A63D-F47909D1D7F3 Q35923086-C00582BE-3FB0-445B-BAC1-E16CBA7845B4 Q36520637-621DF601-DAEF-4E82-B8E3-341E48F58947 Q36634612-07E6AD58-85AD-4781-BFBE-E49B9AA95079 Q37219043-8EC2D64A-6393-4312-9E48-709F7993FCC2 Q37803235-7CF1EF3A-D64C-48CA-9133-EC27D4C9FE4B Q37885161-7BB2C3E2-7DB1-4A49-BC56-F6C6A523F930 Q38063460-3B9BBF36-0030-4E11-A7D6-787EF3DEB08F Q38068099-510AAA82-9F68-4537-91A8-C89CDF4624C7 Q38099698-3D864A4D-46AA-45F7-AEC0-ED1D721A78F0 Q38163610-24EA5D44-8332-4B40-B5D0-957151DB42AA Q38199755-20649278-4B4F-4E90-B184-78879F155DFB Q38229242-CEA3C018-FF5F-4E83-A0B0-BA7DB49077D8 Q38273327-49EED954-2266-4CAF-B91F-E3A88D385392 Q38812543-84379287-1663-405F-8FCA-C43AC6CC5D6D

P2860

The HALT polycystic kidney disease trials: design and implementation.

http://www.wikidata.org/entity/Q33571347

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The HALT polycystic kidney disease trials: design and implementation.

@ast

The HALT polycystic kidney disease trials: design and implementation.

@en

The HALT polycystic kidney disease trials: design and implementation.

@nl

type

label

The HALT polycystic kidney disease trials: design and implementation.

@ast

The HALT polycystic kidney disease trials: design and implementation.

@en

The HALT polycystic kidney disease trials: design and implementation.

@nl

prefLabel

The HALT polycystic kidney disease trials: design and implementation.

@ast

The HALT polycystic kidney disease trials: design and implementation.

@en

The HALT polycystic kidney disease trials: design and implementation.

@nl

P1433

Q33571347-91750401-D6AD-41B2-8A1A-A5D8C69CCA82

P1476

Q33571347-E3A88D54-86B3-4200-B7E9-BE2CDA5DC1DD

P2093

Q33571347-2FED6B4F-D1A9-4AE3-B820-7A1F06B229BC

Q33571347-30FD21FE-F853-431B-B580-259EAA77C87A

Q33571347-4C80790A-9FD9-4590-99F3-9AA446F26CE8

Q33571347-5DC5DBE6-F365-46B8-B7D0-A1B8A65E76A3

Q33571347-705A8A29-5D6D-4CED-9C64-9BA5E4719027

Q33571347-8C03A3C1-BC84-4EAC-B8C1-096E80B71722

Q33571347-A5290875-A98D-4664-ADF8-ADAE71B5ACB4

Q33571347-ADA9770B-5652-4DD8-A233-03707576B63A

Q33571347-B43F2D9D-D5CA-442F-BE21-2ED1BA3C6256

Q33571347-C1718438-30E8-424B-A743-B4C50C34F88B

P2860

Q33571347-01926C98-1E35-4DE5-BE6C-4D915772C41B

Q33571347-0365D2C8-6BED-4A34-86D0-53C70A248FAD

Q33571347-0B262FF9-7FAA-4EE3-8B76-63914080EE57

Q33571347-1CAB184E-A564-4F93-94BF-A581CA58EDEB

Q33571347-33737935-BBE2-4AEA-AAF6-CB970B1162D0

Q33571347-39016706-1D0F-4221-B6CB-87467B880F10

Q33571347-49E6AA6E-6D38-4C4B-8010-A4766E494019

Q33571347-60B78860-2A72-4471-8F06-46C9192D2A93

Q33571347-6C89D3C9-D2A3-4FAE-A339-9DAC4E72FBF5

Q33571347-7562A021-25A6-4250-AC51-7B5569E22FD0

P304

Q33571347-0FBE6697-2BAD-4AE7-BCBF-7172094ADB8B

P31

Q33571347-F4F7F841-9EFB-436A-858D-A5D62BC2A1BD

P356

Q33571347-E78508F5-8F35-44A6-AF8B-CD1774A7FA03

P433

Q33571347-AA25F974-8A7D-4AEB-9A77-8557852FAC8E

P478

Q33571347-C0F0A2F7-66F4-4B0F-B9E5-4670D3CFEEE2

P50

Q33571347-01BF1793-8622-43F1-B8EA-D10B1506FA02

Q33571347-446F7985-EBB0-4348-9E03-84C0F6851EAB

P577

Q33571347-DE777FD1-57F5-415C-AE08-4FDA9B57E83D

P698

Q33571347-FC11AB04-4EA4-4A3F-920D-8F52A8DF2D75

P932

Q33571347-7F190FD3-7EF4-4A7E-B3BE-76086CD20EE1

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

The HALT polycystic kidney disease trials: design and implementation.

@en

P2093

Amirali Masoumi

http://www.w3.org/2001/XMLSchema#string

Arlene B Chapman

http://www.w3.org/2001/XMLSchema#string

Cass Kelleher

http://www.w3.org/2001/XMLSchema#string

Catherine M Meyers

http://www.w3.org/2001/XMLSchema#string

Dana C Miskulin

http://www.w3.org/2001/XMLSchema#string

Franz T Winklhofer

http://www.w3.org/2001/XMLSchema#string

Frederic Rahbari Oskoui

http://www.w3.org/2001/XMLSchema#string

Kyongtae T Bae

http://www.w3.org/2001/XMLSchema#string

Marie C Hogan

http://www.w3.org/2001/XMLSchema#string

Paul A Thompson

http://www.w3.org/2001/XMLSchema#string

P2860

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Random-effects models for longitudinal data

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes.

Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?

Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.

Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.

Creatinine excretion as a measure of protein nutrition in adults of varying age.

The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.

Changing frequency of interim analysis in sequential monitoring.

P304

102-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04310709

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

J Philip Miller

Robert W Schrier

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20089507

http://www.w3.org/2001/XMLSchema#string

P932

2801653

http://www.w3.org/2001/XMLSchema#string